Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Using co-creation and multi-criteria decision analysis to close service gaps for underserved populations.

Mortimer D, Iezzi A, Dickins M, Johnstone G, Lowthian J, Enticott J, Ogrin R.

Health Expect. 2019 Jun 11. doi: 10.1111/hex.12923. [Epub ahead of print]

PMID:
31187600
2.

Profile of home nursing clients with mental health diagnoses: Epidemiological analysis of Australian community home nursing data.

Dickins M, Enticott J, Williams B.

Health Soc Care Community. 2019 Feb 27. doi: 10.1111/hsc.12725. [Epub ahead of print]

PMID:
30815957
3.

Understanding the conceptualisation of risk in the context of community dementia care.

Dickins M, Goeman D, O'Keefe F, Iliffe S, Pond D.

Soc Sci Med. 2018 Jul;208:72-79. doi: 10.1016/j.socscimed.2018.05.018. Epub 2018 May 9.

4.

Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.

Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K.

Clin Pharmacol Ther. 2018 Dec;104(6):1229-1239. doi: 10.1002/cpt.1085. Epub 2018 Apr 27.

5.
6.

Change Strategies and Associated Implementation Challenges: An Analysis of Online Counselling Sessions.

Rodda SN, Hing N, Hodgins DC, Cheetham A, Dickins M, Lubman DI.

J Gambl Stud. 2017 Sep;33(3):955-973. doi: 10.1007/s10899-016-9661-3.

PMID:
27988863
7.

Social inclusion and the Fatosphere: the role of an online weblogging community in fostering social inclusion.

Dickins M, Browning C, Feldman S, Thomas S.

Sociol Health Illn. 2016 Jun;38(5):797-811. doi: 10.1111/1467-9566.12397. Epub 2016 Jan 22.

PMID:
26799865
8.

The health and service needs of older veterans: a qualitative analysis.

Feldman S, Dickins ML, Browning CJ, DeSoysa TS.

Health Expect. 2015 Dec;18(6):2202-12. doi: 10.1111/hex.12190. Epub 2014 Mar 24.

9.

Translating research findings into community based theatre: More than a dead man's wife.

Feldman S, Hopgood A, Dickins M.

J Aging Stud. 2013 Dec;27(4):476-86. doi: 10.1016/j.jaging.2013.03.007. Epub 2013 Jul 18.

PMID:
24300067
10.

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

Fenner KS, Jones HM, Ullah M, Kempshall S, Dickins M, Lai Y, Morgan P, Barton HA.

Xenobiotica. 2012 Jan;42(1):28-45. doi: 10.3109/00498254.2011.626464. Epub 2011 Nov 11. Review.

PMID:
22077101
11.

Application of PBPK modelling in drug discovery and development at Pfizer.

Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, Gurrell IK, Logan YR, Bungay PJ, Jones BC, Gardner IB.

Xenobiotica. 2012 Jan;42(1):94-106. doi: 10.3109/00498254.2011.627477. Epub 2011 Oct 30.

PMID:
22035569
12.

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.

Harrison A, Gardner I, Hay T, Dickins M, Beaumont K, Phipps A, Purkins L, Allan G, Christian R, Duckworth J, Gurrell I, Kempshall S, Savage M, Seymour M, Simpson M, Taylor L, Turnpenny P.

Xenobiotica. 2012 Jan;42(1):57-74. doi: 10.3109/00498254.2011.622418. Epub 2011 Oct 12.

PMID:
21992032
13.

The role of the fatosphere in fat adults' responses to obesity stigma: a model of empowerment without a focus on weight loss.

Dickins M, Thomas SL, King B, Lewis S, Holland K.

Qual Health Res. 2011 Dec;21(12):1679-91. doi: 10.1177/1049732311417728. Epub 2011 Aug 2.

PMID:
21810992
14.

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.

Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K.

Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x.

15.

Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.

Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S.

Clin Pharmacokinet. 2011 May;50(5):331-47. doi: 10.2165/11539680-000000000-00000.

PMID:
21456633
16.

An evaluation of ondansetron binding interactions with human cytochrome P450 enzymes CYP3A4 and CYP2D6.

Lewis DF, Ito Y, Eddershaw PJ, Dickins M, Goldfarb PS.

Drug Metab Lett. 2010 Jan;4(1):25-30.

PMID:
20201779
17.

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.

Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS.

Drug Metab Dispos. 2009 Aug;37(8):1658-66. doi: 10.1124/dmd.108.026252. Epub 2009 Apr 30.

PMID:
19406954
18.

Maraviroc: in vitro assessment of drug-drug interaction potential.

Hyland R, Dickins M, Collins C, Jones H, Jones B.

Br J Clin Pharmacol. 2008 Oct;66(4):498-507. doi: 10.1111/j.1365-2125.2008.03198.x. Epub 2008 Apr 10.

19.

Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.

Allan G, Davis J, Dickins M, Gardner I, Jenkins T, Jones H, Webster R, Westgate H.

Xenobiotica. 2008 Jun;38(6):620-40. doi: 10.1080/00498250802069088 .

PMID:
18570162
20.

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.

Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S, Plowchalk DR, Cook J, Guo F, Obach RS.

Br J Clin Pharmacol. 2008 May;65(5):680-92. doi: 10.1111/j.1365-2125.2007.03070.x. Epub 2008 Feb 14.

21.

The time to move cytochrome p450 induction into mainstream pharmacology is long overdue.

Smith DA, Dickins M, Fahmi OA, Iwasaki K, Lee C, Obach RS, Padbury G, De Morais SM, Ripp SL, Stevens J, Voorman R, Youdim K.

Drug Metab Dispos. 2007 Apr;35(4):697-8. No abstract available.

PMID:
17384203
22.
23.

Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes.

Lewis DF, Lake BG, Ito Y, Dickins M.

J Enzyme Inhib Med Chem. 2006 Aug;21(4):385-9.

PMID:
17059170
24.
25.

Induction of cytochromes P450.

Dickins M.

Curr Top Med Chem. 2004;4(16):1745-66. Review.

PMID:
15579106
26.

Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism.

Lewis DF, Lake BG, Dickins M.

Drug Metabol Drug Interact. 2004;20(3):111-42. Review.

PMID:
15508429
27.

Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions.

Lewis DF, Lake BG, Dickins M, Goldfarb PS.

Xenobiotica. 2004 Jun;34(6):549-69.

PMID:
15277015
29.

Compound lipophilicity for substrate binding to human P450s in drug metabolism.

Lewis DF, Jacobs MN, Dickins M.

Drug Discov Today. 2004 Jun 15;9(12):530-7. Review.

PMID:
15183161
30.
31.
32.

Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactions.

Lewis DF, Lake BG, Dickins M, Goldfarb PS.

Drug Metabol Drug Interact. 2002;19(2):115-35.

PMID:
12751910
34.
35.

Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure.

Lewis DF, Lake BG, Dickins M, Ueng YF, Goldfarb PS.

Xenobiotica. 2003 Mar;33(3):239-54.

PMID:
12637242
36.

Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism.

Lewis DF, Dickins M.

Drug Metab Rev. 2003 Feb;35(1):1-18. Review.

PMID:
12635813
37.

The importance of predictive ADME simulation.

Dickins M, Modi S.

Drug Discov Today. 2002 Jul 15;7(14):755-6. No abstract available.

PMID:
12547029
38.

Substrate SARs in human P450s.

Lewis DF, Dickins M.

Drug Discov Today. 2002 Sep 1;7(17):918-25. Review.

PMID:
12546935
39.

Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions.

Lewis DF, Lake BG, Bird MG, Loizou GD, Dickins M, Goldfarb PS.

Toxicol In Vitro. 2003 Feb;17(1):93-105.

PMID:
12537967
40.

Diversity of Campylobacter isolates from retail poultry carcasses and from humans as demonstrated by pulsed-field gel electrophoresis.

Dickins MA, Franklin S, Stefanova R, Schutze GE, Eisenach KD, Wesley I, Cave MD.

J Food Prot. 2002 Jun;65(6):957-62.

PMID:
12092728
43.

Structure-activity relationship for human cytochrome P450 substrates and inhibitors.

Lewis DF, Modi S, Dickins M.

Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. Review.

PMID:
11996013
44.
45.

Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism.

Lewis DF, Modi S, Dickins M.

Drug Metabol Drug Interact. 2001;18(3-4):221-42. Review.

PMID:
11791886
47.

An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).

Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S.

Br J Clin Pharmacol. 2001 Nov;52(5):555-61.

48.

Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries.

Lewis DF, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS.

Drug Metabol Drug Interact. 1999;15(1):1-49. Review.

PMID:
10707112
50.

Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.

Lewis DF, Lake BG, George SG, Dickins M, Eddershaw PJ, Tarbit MH, Beresford AP, Goldfarb PS, Guengerich FP.

Toxicology. 1999 Nov 29;139(1-2):53-79.

PMID:
10614688

Supplemental Content

Loading ...
Support Center